<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALTEPLASE RECOMBINANT <img border="0" src="../images/pr.gif"/></span><br/>(al'te-plase)<br/><span class="topboxtradename">Actilyse, </span><span class="topboxtradename">Activase, </span><span class="topboxtradename">Cathflo Activase<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">thrombolytic enzyme</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>This recombinant DNA-derived form of human tissue-type plasminogen activator (t-PA) is a thrombolytic agent.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The agent t-PA promotes thrombolysis by forming the active proteolytic enzyme plasmin. Plasmin is capable of degrading fibrin,
         fibrinogen, and factors V, VIII, and XII.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Indicated in selective cases of acute MI, preferably within 6 h of attack for recanalization of the coronary artery; lysis
         of acute pulmonary emboli; acute ischemic stroke or thrombotic stroke (within 3 h of onset); treatment of acute coronary artery
         thrombosis in the setting of percutaneous coronary intervention (PCI); reestablishing patency of occluded IV catheter.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Lysis of arterial occlusions in peripheral and bypass vessels; DVT.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Active internal bleeding, history of cerebrovascular accident, recent (within 2 mo) intracranial or interspinal surgery or
         trauma, intracranial neoplasm, arteriovenous malformation, bleeding disorders, severe uncontrolled hypertension, likelihood
         of left heart thrombus, acute pericarditis, bacterial endocarditis, severe liver dysfunction, age &gt;75, pregnancy (category
         C), septic thrombophlebitis, current use of oral anticoagulants.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Recent major surgery (within 10 d), cerebral vascular disease, recent GI or GU bleeding, recent trauma, hypertension, lactation,
         hemorrhagic ophthalmic conditions. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute MI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> <img src="../images/special/greaterorequal.gif"/>65 kg: 60 mg over first hour, with 610 mg infused over first 12
               min; then 20 mg/h over the second hour and 20 mg over the third hour (100 mg over 3 h); accelerated schedule, 15-mg bolus, then 0.75 mg/kg (up to 50 mg) over 30 min, then 0.5 mg/kg (up to 35 mg) over 60 min<br/><br/><span class="indicationtitle">Acute Ischemic Stroke/Thrombotic Stroke</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.9 mg/kg over 60 min with 10% of dose as an initial bolus over 1 min (max: 90 mg)<br/><br/><span class="indicationtitle">Pulmonary Embolism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 100 mg infused over 2 h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.10.6 mg/kg/hr <small>x</small> 6 h<br/><br/><span class="indicationtitle">Reopen Occluded IV Catheter</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>&gt;30 kg:</i> Instill 2 mg/2 mL into dysfunctional catheter for 2 h. May repeat once if needed.<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i>&gt;2 y, 1029 kg:</i> Instill 110% of internal lumen volume with 1 mg/mL concentration (max 2 mg). May repeat if function not restored within
               2 h. <b>IV</b>
<i> 0.5 mg diluted in a volume to fill the lumen of the catheter.<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Reconstitute the 50-mg vial as follows: Do not use if vacuum in vial has been broken. Use a large-bore needle (e.g., 18 gauge)
                  and do not prime needle with air.  Dilute contents of vial with sterile water for injection supplied by manufacturer. Direct stream of sterile water into the lyophilized cake. Slight foaming is usual. Allow to stand until bubbles dissipate.
                  Resulting concentration is 1 mg/mL. Reconstitute the 100-mg vial as follows: The 100-mg vial does not contain a vacuum. Use supplied transfer device for reconstitution
                  and follow manufacturer's directions. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>  Start IV infusion as soon as possible after the thrombolytic event, preferably within 6 h. Administer drug as reconstituted (1 mg/mL) or further diluted with an equal volume of NS or D5W to yield 0.5 mg/mL. <span class="methodtype">Acute MI:</span>  Administer 60% of total dose in the first hour for acute MI, with 610% given as a bolus dose over 12 min
                  and remainder of first dose infused over hour 1. Follow with second dose (20% of total) over hour 2, and third dose (20%
                  of total) over hour 3.  For patients weighing Pulmonary embolism:  Administer entire dose over a 2 h period. <span class="methodtype">Acute ischemic stroke:</span>  Give 5 mg as an initial bolus over 1 min, then give the remainder of the 0.75 mg/kg dose over 60 min. Do not exceed a total dose of 100 mg. Higher doses have been associated with intracranial bleeding.  Follow infusion of drug by flushing IV tubing with 3050 mL of NS or D5W.  Reconstituted drug is stable for 8 h in above solutions at room temperature (2°30° C; 36°86°
                  F). Since there are no preservatives, discard any unused solution after that time. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store above reconstituted solutions at room temperature 2°30° C (36°86° F) for no longer than
            8 h. Discard any unused solution after that time.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span> Internal and superficial bleeding (cerebral, retroperitoneal, GU, GI). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 510 min after infusion completed. <span class="typehead">Duration:</span> Baseline values restored in 3 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 26.5 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of excess bleeding q15min for the first hour of therapy, q30min for second to eighth hour, then q8h. Monitor
            neurological checks throughout drug infusion q30min and qh for the first 8 h after infusion.
         </li>
<li>Protect patient from invasive procedures because spontaneous bleeding occurs twice as often with alteplase as with heparin.
            IM injections are contraindicated. Also prevent physical manipulation of patient during thrombolytic therapy to prevent bruising.
         </li>
<li>Lab tests: Coagulation tests including APTT, bleeding time, PT, TT, INR, must be done before administration of drug. Also
            check <i>baseline</i> Hct, Hgb, and platelet counts, in case of bleeding. Draw Hct following drug administration to detect possible blood loss.
         </li>
<li>Keep patient in bed while receiving this medication.</li>
<li>Check vital signs frequently. Be alert to changes in cardiac rhythm.</li>
<li>Stop therapy immediately if dysrhythmias occur.</li>
<li>Report signs of bleeding: gum bleeding, epistaxis, hematoma, spontaneous ecchymoses, oozing at catheter site, increased pain
            from internal bleeding. Stop the infusion, then resume when bleeding stops.
         </li>
<li>Use the radial artery to draw ABGs. Pressure to puncture sites, if necessary, should be maintained for up to 30 min.</li>
<li>Continue monitoring vital signs until laboratory reports confirm anticoagulant control; patient is at risk for postthrombolytic
            bleeding for 24 d after intracoronary alteplase treatment.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately a sudden severe headache.</li>
<li>Report blood in urine and bloody or tarry stools.</li>
<li>Report any signs of bleeding or oozing from cuts or places of injection.</li>
<li>Remain quiet and on bedrest while receiving this medicine.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>